Dr B Sandeep - The Cancer Doctor (@drbammidi) 's Twitter Profile
Dr B Sandeep - The Cancer Doctor

@drbammidi

#SurgicalOncologist #సత్యమేవజయతే #cancersurgeon

ID: 1181724792036020224

linkhttps://instagram.com/drbammidi?igshid=MjEwN2IyYWYwYw== calendar_today09-10-2019 00:15:33

1,1K Tweet

267 Followers

208 Following

Dr Abhijeet Ashok Salunke (@bonestumor) 's Twitter Profile Photo

📢 Excited to share 🦵 Salunke’s GCRI Surgical Technique for neopatellar ligament reconstruction using hamstring tendon in proximal tibia tumour megaprosthesis. Novel approach to restore knee stability after limb salvage surgery boneandjoint.org.uk/Article/10.130… Bone & Joint Open

Diego A. Díaz García (@diegoadiazg) 's Twitter Profile Photo

🧬 Pulmonary neuroendocrine neoplasms: evolving molecular insights are reshaping diagnosis & treatment. 🔹 New biomarkers & functional imaging 🔹 Molecular classification advances 🔹 Challenges in adjuvant & metastatic settings 📖 The Lancet Oncology DOI:

🧬 Pulmonary neuroendocrine neoplasms: evolving molecular insights are reshaping diagnosis & treatment.

🔹 New biomarkers & functional imaging
🔹 Molecular classification advances
🔹 Challenges in adjuvant & metastatic settings

📖 <a href="/TheLancetOncol/">The Lancet Oncology</a>
DOI:
National Medical Commission (@nmc_bharat) 's Twitter Profile Photo

National Medical Commission(NMC) has decided to fully shift to FACE based AEBAS authentication for faculty attendance from 1st MAY 2025. #NMC #AEBAS

National Medical Commission(NMC) has decided to fully shift to FACE based AEBAS authentication for faculty attendance from 1st MAY 2025.

#NMC #AEBAS
TMC Radiation Oncology (@radonctmc) 's Twitter Profile Photo

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)

Honored to share highlights of <a href="/ReenaEngineer/">Reena Engineer</a>’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer
Neoadj CRT vs CT alone:
🌟 Nearly doubled mOS (21.8 vs 10.1 months)
🌟 Significantly improved R0 resection (51.6% vs 29.7%)